Australia's most trusted
source of pharma news
Posted 22 December 2025 AM
The PBAC has delivered hopeful news to the 420,000 or so Australians using GLP-1s on private script, saying some populations would benefit from subsidised access and going so far as to recommend one in the same meeting. However, it added the PBS is not a viable path for "preventative" access.
Novo Nordisk's Wegovy has become the first obesity treatment to be recommended for subsidy on the PBS, seemingly fitting all the criteria the Committee raised in the advice it gave to the government on funding GLP-1 medications to treat obesity.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.